An experimental brain tumor vaccine showed encouraging long-term survival results in a small early-stage trial. Digest
Some brain tumors remain incurable even after surgery, radiation, and chemotherapy and are often linked to a short life expectancy. To explore a potential new therapy, researchers analyzed long-term data from an earlier brain tumor vaccine trial to determine whether the treatment was associated with longer survival and improved tumor control.
You just missed this in your inbox
Every other week our Premium Members received this exact study plus Rhonda's practical commentary and 8+ other hand-picked papers.
The original trial enrolled 33 adults with newly diagnosed astrocytoma, a brain tumor named for its resemblance to astrocytes, star-shaped cells that help support nerve cells by supplying nutrients and maintaining a healthy environment around them. Their tumors were classified as grade III or IV under the 2007 World Health Organization system, meaning they had features linked to more aggressive disease. Every tumor also carried the same mutation in IDH1, a gene involved in cell metabolism that is often altered in adult astrocytomas. The mutation changes the IDH1 protein, creating an abnormal protein fragment that is present in the tumor but not in healthy cells. The vaccine takes advantage of that alteration. It contains a synthetic version of this abnormal protein fragment, which researchers hoped would train the immune system to recognize tumor cells carrying the mutation. Thirty-two participants received at least one vaccine dose as part of a schedule of eight injections over about six months following diagnosis, in addition to radiation, chemotherapy, or both. Of those participants, 30 provided enough blood samples for researchers to analyze their immune responses.
- Eight years after diagnosis, 66% of the treated participants were still alive, while 42% had survived without tumor growth or recurrence.
- Among the 11 participants with grade IV tumors, median survival (the point at which half were still alive) was about 8.8 years, compared with roughly 2.6 to 4.7 years reported in earlier studies that did not involve the vaccine.
- Most participants developed an immune response against the mutated IDH1 protein. Immune-cell responses to mutated IDH1 were detected in 28 of 32 treated participants and antibodies were detected in 30 of 32. Two participants who showed no measurable immune response experienced tumor progression within two years and died within three years of diagnosis.
- The timing of antibody responses appeared to be linked to better outcomes. During 47 weeks of monitoring, participants whose response was strongest at the final vaccination or afterward tended to remain free of progression and survive longer than those whose response peaked earlier.
The study also provided a glimpse of the vaccine-induced immune response inside the brain. In one participant, an enlarging area on magnetic resonance imaging (MRI) scans initially looked like tumor growth. However, tissue removed from that area instead showed substantial inflammation and contained immune cells that recognized the mutated IDH1 target. Although this evidence came from only one participant, it suggests that the vaccine could generate a targeted immune response within the brain.
Because this was a small, early-stage trial with no comparison group, it cannot prove that the vaccine is safe or that it improved survival. The survival results are also difficult to compare with earlier studies because the trial included a selected group of patients, more than half had their tumors completely removed, and tumor-grading systems have changed over time. Mutation-targeted vaccination for astrocytoma therefore remains investigational, but these data support its promise as a strategy for future cancer treatment. In episode #113, Dr. Derya Unutmaz explains how AI could enable more precise, personalized cancer treatments by identifying tumor-specific mutations and designing therapies to target them.